Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Spinocerebellar Degenerations 1Rectal Neoplasms 1Neoplasms 1Locally Advanced Solid Tumor 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 178Paclitaxel 79Radiotherapy 76Carboplatin 70Brachytherapy 69pembrolizumab 63Bevacizumab 40Gemcitabine 28Radiation 27Topotecan 26Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 25Nivolumab 22Colposcopy 22human papillomavirus vaccine, L1 type 16, 18 21Magnetic Resonance Spectroscopy 21Drug Therapy 20atezolizumab 19Platinum 19Papillomavirus Vaccines 18Radiotherapy, Intensity-Modulated 17Docetaxel 17Taxes 16Cyclophosphamide 16Biopsy 16Early Intervention, Educational 151,2-diaminocyclohexaneplatinum II citrate 15Methods 14Blood Specimen Collection 14fludarabine 13Injections 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Uterine Cervical Neoplasms × E7046 × Clear all
NCT04432857 2024-06-27

AN0025 and Pembrolizumab Combination in Advanced Solid Tumors

Adlai Nortye Biopharma Co., Ltd.

Phase 1 Active not recruiting
63 enrolled
BreastGastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Spinocerebellar Degenerations, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡